Risks of rhG-CSF treatment in drug-induced agranulocytosis.
Nine patients with drug-induced agranulocytosis received recombinant human granulocyte colony-stimulating factor (rhG-CSF) to accelerate myeloid recovery because of life-threatening infections related to neutropenia. All patients showed a quick recovery of their granulocyte counts. Side effects were substantial, however. Three patients, two with a severe infection and one with preexisting pulmonary infiltrates, developed worsening of their respiratory status during neutrophil recovery, resulting in clinical manifestations of the adult respiratory distress syndrome (ARDS). In view of these major complications, the exact place of hematopoietic growth factors in the treatment of drug-induced agranulocytosis remains to be determined.
Demuynck
H
H
Department of Hematology, University Hospital Gasthuisberg, Leuven, Belgium.
Zachée
P
P
Verhoef
G E
GE
Schetz
M
M
Van den Berghe
G
G
Lauwers
P
P
Boogaerts
M A
MA
D000328:Adult; D000368:Aged; D000380:Agranulocytosis / Q000139:chemically induced* / Q000453:epidemiology / Q000628:therapy*; D001853:Bone Marrow / Q000187:drug effects; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D007958:Leukocyte Count / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009504:Neutrophils; D011994:Recombinant Proteins / Q000627:therapeutic use; D012128:Respiratory Distress Syndrome / Q000209:etiology; D012307:Risk Factors
D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor